Doximity (DOCS) Stock Skyrockets 105% on Bold AI Strategy Announcement

Key Highlights

• DOCS shares skyrocketed 105% in premarket hours to $42.39 even after falling short of EPS projections by 4.2%
• Company leadership highlighted what CEO Jeff Tangney described as a “once-in-a-generation opportunity” in clinical artificial intelligence
• Stanford/Harvard research showed Doximity’s Ask AI platform exceeded performance of leading competitors, including Anthropic’s Fable 5
• The platform’s Scribe note-taking feature saw a tenfold increase in users by July versus the previous year
• Quarterly revenue reached $156.6 million, representing 7.3% annual growth and exceeding projections; annual revenue forecast upgraded to $676 million

Shares of the physician networking platform Doximity exploded 105% higher during Friday’s premarket session, reaching $42.39, as the company’s quarterly earnings presentation ignited investor enthusiasm despite falling short on profit expectations.

Doximity, Inc., DOCS

Financial results for the period presented a nuanced picture. The company reported $156.6 million in quarterly revenue, marking a 7.3% increase from the prior year and surpassing Wall Street’s $151.3 million projection by 3.5%. However, adjusted earnings per share landed at $0.29, falling short of the $0.30 analyst consensus by 4.2%. On a brighter note, adjusted EBITDA reached $74.77 million, exceeding forecasts by 7.4%.

What triggered the dramatic stock movement? The answer lies in artificial intelligence.

Shares remained relatively stable until CEO Jeff Tangney discussed the company’s artificial intelligence initiatives during the conference call. “We’re demonstrating that maintaining industry-leading software margins while aggressively investing in clinical AI is entirely achievable,” Tangney stated.

The CEO characterized the moment as a “once-in-a-generation opportunity to construct the AI-powered future of medicine.” This message resonated powerfully with market participants.

Artificial Intelligence Performance Takes Spotlight

According to recent research conducted by academic teams from Stanford and Harvard evaluating medical AI platforms, Doximity’s Ask AI solution delivered superior performance compared to competing U.S. systems, including Anthropic’s Fable 5.

Engagement with Doximity’s suite of AI-powered tools experienced substantial growth throughout the reporting period. The company’s Scribe note-taking feature witnessed a tenfold surge in active users by July when measured against the comparable period twelve months earlier.

Similarly, utilization of the Search AI functionality increased during the quarter, demonstrating expanding adoption of the platform’s artificial intelligence capabilities.

“We’ve established ourselves as the digital platform for physicians, and AI represents the next evolutionary phase of our expansion,” Tangney emphasized during the earnings discussion.

Forward Outlook and Financial Metrics

Looking ahead to the upcoming quarter, Doximity projected revenue between $170 million and $171 million, with a midpoint target of $170.5 million. While this guidance aligned closely with analyst expectations, it fell marginally below some Wall Street forecasts.

Management elevated full-year revenue guidance to a midpoint of $676 million, representing an increase from the previously stated $670 million target.

The company’s full-year EBITDA projection landed at a $319 million midpoint, falling below the $329.2 million analyst consensus.

Quarterly operating margin registered at 21.5%, declining from 37.4% in the year-ago period. Free cash flow margin measured 25.3%, compared with 73.8% in the preceding quarter.

Billings at period end totaled $159.3 million, representing a 7% year-over-year increase.

The company entered Friday with a market capitalization of $3.89 billion. Following the 105% premarket surge, that valuation transformed dramatically.

Examining longer-term performance, Doximity has achieved a 21.9% compounded annual revenue growth rate over the past five years. The two-year annualized growth rate stands at 15.2%, indicating deceleration, while sell-side analysts project revenue growth of approximately 3.6% over the coming 12-month period.

The most current data released by the company showed Scribe note-taking users increased tenfold in July compared to the same month in the previous year.

The post Doximity (DOCS) Stock Skyrockets 105% on Bold AI Strategy Announcement appeared first on Blockonomi.